35 results about "Stimulant" patented technology

The invention relates to a co-crystal or salt comprising psilocin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.

The invention discloses a method for preparing a biostimulant from a hydrothermal carbonization solution. The method comprises the following steps: hydrothermal carbonization of biomass wastes, dilution of the hydrothermal carbonization solution, domestication of activated sludge and enhancement of synergistic functional bacteria, and aerobic treatment. The invention also discloses an application effect of the hydrothermal carbonization liquid. By means of the method, substances which are toxic to crop growth in the hydrothermal carbonization liquid can be effectively removed, a biostimulant functional product which has a promoting effect on crop growth is prepared, the technological process is green and environmentally friendly, the raw material adaptability is wide, the technology is stable, and good application prospects are achieved.

To provide an alcoholic beverage that achieves reduction in stimulation from alcohol and / or an odd flavor of alcohol after drinking.SOLUTION: An alcoholic beverage includes cinnamaldehyde and / or terpinyl acetate.SELECTED DRAWING: None

The invention discloses an integrated device with rubber tapping and stimulant smearing functions. The integrated device comprises a magnetic attraction supporting guide rail, a circumferential sliding device, a lifting control device and a multifunctional execution device. The multifunctional execution device comprises a rubber tapping execution assembly and a brush head execution assembly, in the rising stroke, the rubber tapping execution assembly conducts rubber tapping operation, and meanwhile the brush head execution assembly conducts dry brushing pre-cleaning on the surface of a rubber tapping tree below a rubber tapping opening along with the movement track; in the descending stroke, the brush head execution assembly smears the stimulation liquid on the surface of the pre-cleaned rubber tapping tree, and meanwhile the rubber tapping execution assembly is reset; the rubber tapping execution assembly and the brush head execution assembly are installed in the same device, the rubber tapping function and the stimulation liquid smearing function are integrated in the same device, multiple purposes are achieved through one machine, the working efficiency is remarkably higher than that of manual work, the labor intensity is greatly reduced, precise delayed smearing after rubber tapping is achieved through program control, the stimulation effect is stable, and the application range is wide. The rubber yield can be improved.

The invention provides a lipidoid Toll-like receptor agonist derivative as well as preparation and application thereof, and particularly provides a compound as shown in a formula I, a preparation method of the compound and application of the compound as a TLR7 and / or TLR8 agonist. The compounds can be used as immunostimulators and adjuvants.

The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and n are defined as in claim 1, which are ghrelin O-acyl transferase (GOAT) inhibitors for use in the treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.

The present disclosure provides at least one anxiolytic; and at least one stimulant; and a composition comprising: at least one anxiolytic; at least one stimulant; and a pharmaceutically acceptable carrier. Methods of treating a subject having a condition, such as a central nervous system disorder, comprising administering to the subject having a condition, at least one anxiolytic; and at least one stimulant, where the administering of the active ingredients, i.e., at least one anxiolytic and at least one stimulant, may occur together, separately, sequentially, and / or simultaneously. These active ingredients may be provided to a subject suffering from a condition in an amount sufficient to treat the condition in the subject in need thereof, where the treatment prevents, alleviates, reduces, eliminates, or interferes with at least one of the symptoms associated with the condition.

The objective is to provide a novel carbon dioxide stimulation enhancer. [Solution] N-(heptan-4-yl)benzo[d][1,3]dioxol-5-carboxamide is used as a carbonation stimulant enhancer. Furthermore, it is also possible to use spirantol or the like in combination.

In some embodiments, the present invention discloses a method for treating drug overdose, comprising administering a therapeutically effective amount of a respiratory stimulant to a patient in need, wherein the overdose drug comprises an α2-adrenergic receptor agonist.

The embodiment of the invention provides a water-based moistening atomized liquid and a preparation method thereof, the water-based moistening atomized liquid is applied to ultrasonic atomization, and the water-based moistening atomized liquid comprises the following components in parts by weight: 70-90 parts of deionized water; 5-20 parts of a humectant; 1-3 parts of a moistening agent; 0.1-0.2 part of a body fluid generating agent; 0.1 to 0.2 part of a pH buffer agent; wherein the moistening agent is prepared from at least one of trehalose, panthenol, sodium hyaluronate, erythritol, sorbitol and menthol. According to the water-based moistening-enhancing atomized liquid and the preparation method thereof provided by the embodiment of the invention, by optimizing the viscosity and selecting the functional components, the efficient, stable and lasting atomization process is realized. The atomization sheet is not easy to block, and the service life is prolonged; the generated aerosol liquid drops are fine and uniform, the coalescence tendency is low in the conveying process, the condensation liquid accumulation phenomenon is effectively inhibited, and the use reliability of the product and the user experience are improved.

The invention relates to a nasal administration composition containing a GLP-1 receptor stimulant and a preparation method and application thereof. In-vivo and in-vitro tests show that the composition has good stability, good bioavailability is achieved after nasal administration of rats, and little drug is distributed in brain tissue.

Pharmaceutical formulations comprising buromantan or analogs of buromantan are disclosed, as well as methods of using the formulations for pharmaceutical therapy to reduce withdrawal syndrome and prevent relapse in the treatment of stimulant use disorders, to quit patients from drugs having a predisposition to abuse or addiction, or to promote regression learning in the treatment of mental disorders.

The invention discloses an execution control ability training method and system for children suffering from sleep breathing disorder with cognitive disorder. The training method comprises the steps that an initial difficulty level is acquired, initial parameter configuration is carried out, and a gamification training task is formed; displaying the gamification training task, and recording the answer result of the user to each task test; dynamically adjusting a current task parameter based on a real-time answering result of the user; dynamically switching the current selection rule based on the current task parameter and a preset rule switching logic; wherein the selection rules at least include that the character meaning is the same as the color of the stimulant, the character color is the same as the color of the stimulant, and the physical color of the option is the same as the color of the stimulant; immediate feedback is provided for the user in the task training process of the user; and after the user completes the training, a training result is displayed to the user. The method not only can train the suppression control ability of the user, but also can train the cognitive flexibility of the user based on a multi-rule dynamic switching mechanism.

Various embodiments of the present disclosure describe vaporizable alkaloid compositions that can form an inhalable vapor when dispensed from an electronic device, such as an electronic cigarette. The compositions herein include a substituted pyridine compound in combination with a chemosensory stimulant, which in certain instances includes a spice additive having a heat intensity of about 1,000 to about 20,000,000 Scoville Pungency Units (SHU). A suite of vaporizable alkaloid compositions with decreasing amounts (w / v) of the substituted pyridine compound are provided as part of a smoking cessation program.

An orally administered stimulant. The orally administered stimulant comprising at least 30% of guarana extract; at least 0.1% of polyvinylpyrrolidone; at least 0.1% of xylitol sweetener; at least 0.1% of sucralose; at least 0.1% of natural flavoring; and at least 0.1% of mint extract, wherein the orally administered stimulant is fully mixed into a homogonous solution and dried to form a powder.

1. Name of the product in this design: Rubber Tree Stimulant Containing and Dispensing Device. 2. Purpose of this design: For containing and dispensing rubber tree stimulants. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

This invention discloses the use of at least one growth-active substance selected from (a) and (b) below, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, or an analogue thereof, or an analogue thereof, in the preparation of a medicament, pharmaceutical composition, or formulation for improving, correcting, alleviating, controlling, treating, or preventing ophthalmic diseases or symptoms: (a) growth hormone; (b) a growth hormone secretion stimulant. By administering an effective amount of the growth-active substance to a patient, ophthalmological conditions, especially hyperopia and related symptoms, can be significantly improved, achieving the effect of preventing and treating hyperopia, with good safety and promising clinical application prospects. This invention also provides pharmaceutical compositions, formulations, and devices containing the above-mentioned growth-active substances.

This invention discloses an orally disintegrating film formulation of BPC-157 sodium salt for treating acute alcohol poisoning and its preparation method. It relates to the field of acute alcohol poisoning treatment technology. The orally disintegrating film formulation comprises, by weight percentage: 0.1-5% BPC-157 sodium salt, 40-70% film-forming material, 5-15% plasticizer, 0.1-15% disintegrant, 0.1-15% sweetener, 0.1-10% salivary stimulant, and 1-5% other excipients. This invention prepares an orally disintegrating film formulation of BPC-157 sodium salt, utilizing its rapid dissolution characteristics and the pharmacological effects of BPC-157, providing a new option for treating acute alcohol poisoning. This formulation has advantages such as rapid onset of action, high bioavailability, and few side effects, and is expected to become an effective drug for treating acute alcohol poisoning.

A measurement device including: a support unit for supporting a first container accommodating therein a first solution containing an indicator and frozen, the indicator being to react with a component generated from a biological sample; a heater for heating the first solution in the first container in a support state where the support unit supports the first container; a first addition unit for, in the support state, adding a second solution containing a stimulant to the first solution in the first container, the stimulant being to activate a function of the biological sample; and a second addition unit for, in the support state, adding the biological sample to the first solution in the first container.

Disclosed are pharmaceutical preparations comprising bromantane or an analogue of bromantane, and methods of using said preparations for pharmacotherapy to alleviate withdrawal syndrome and prevent relapse in the treatment of stimulant use disorder, to transition patients off medications that have abuse or addiction liabilities, or to facilitate extinction learning in the treatment of mental disorders.

The invention provides application of an IP receptor stimulant in preparation of a medicine for treating lung injury, and relates to the technical field of biological medicine. Transdifferentiation of alveolar II-type epithelial cells to I-type epithelial cells after lung injury is realized by utilizing selepag and other IP receptor agonists, and the scheme not only can relieve lung tissue inflammation and fibrosis degree induced by bleomycin and other factors, but also can reduce the death rate of model animals and improve lung function prognosis. Meanwhile, the used IP receptor stimulant part is a clinically mastered drug, so that the safety is higher, the selectivity is good, and a new effective way and a new drug development direction are provided for the treatment of lung injury and related fibrosis diseases.

Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and / or drug (sometimes collectively referred to herein as a “therapeutic component”), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and / or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and / or neurodegenerative diseases.

Disclosed herein are compositions that include a combination of: (1) a non-xanthine CNS stimulant or nootropic; (2) a ketone body or ketone body precursor, such as beta-hydroxybutyrate (BHB) salt, BHB ester, BHB acid, acetoacetate salt, acetoacetate ester, acetoacetic acid, 1,3-butanediol, medium chain fatty acid, or ester of medium chain fatty acid; and (3) optionally a dietetically or pharmaceutically acceptable carrier. The composition may include a vasodilator. The composition may include a short or medium chain fatty acid or ester thereof in addition to or instead of the ketone body or ketone body precursor. The composition can provide enhanced cognitive flexibility, improved sustained attention, improved working memory, and neuroprotection in a mammal. The composition can also beneficially increase resting energy expenditure (resting metabolic rate), particularly when in a state of ketosis, enhancing fat loss principally through ketosis while promoting muscle formation and maintenance, as well as modulating lethargy / lightheadedness when entering a ketogenic state.

This invention discloses an intelligent doping risk assessment system and method. The system includes a data acquisition and processing module, a feature extraction module, an intelligent risk assessment module, and an output and decision-making module. The method includes steps one, data acquisition and preprocessing; step two, multi-dimensional feature extraction; step three, intelligent risk assessment; step four, risk level determination; and step five, result generation and output. This invention can automatically integrate and analyze athletes' behavioral patterns, historical records, and other risk characteristics, outputting quantified risk levels and clear decision-making criteria. This enables accurate identification and focused monitoring of high-risk targets, significantly improving the deterrent effect and work efficiency of inspections, optimizing resource allocation, reducing overall costs, and providing objective and interpretable data support for targeted education and management of athletes.

To provide C17, C20 and C21 substituted neuroactive steroids and their methods of use.SOLUTION: Described herein are neuroactive steroids or pharmaceutically acceptable salts thereof. Such compounds are expected, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising the compounds described herein and methods of use and treatment, e.g., for inducing sedation and / or anesthesia. In one aspect, a method for treating epilepsy or status epilepticus in a subject is provided herein.SELECTED DRAWING: None

To provide neuroactive steroids for use in preventing and treating CNS-related conditions, compositions comprising the neuroactive steroids, and methods of treating CNS-related disorders.SOLUTION: Provided herein are 19-nor C3, 3-disubstituted steroids represented by formula (I), and compositions comprising the compound of formula (I). [In the formula, A represents an N-containing 5-membered heterocycle; R1 represents lower alkyl, or lower haloalkyl; R2 and R3 represent H, halo, or the like; and R4 represents a group such as halo, cyano, or lower alkyl.]SELECTED DRAWING: Figure 1

Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and / or drug (sometimes collectively referred to herein as a “therapeutic component”), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and / or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and / or neurodegenerative diseases.

A measurement unit is used for measuring a characteristic of a biological sample. The measurement unit includes a second solution containing a stimulant configured to activate a function of the biological sample and an organic solvent configured to dissolve the stimulant, a second container configured to house the frozen second solution, and a sealing bag configured to house the second container in its sealed internal space.